The protective effect of a<scp>DNA</scp>vaccine encoding the<i>Toxoplasma gondii</i>cyclophilin gene in<scp>BALB/c</scp>mice

Gong, Pengtao; Huang, Xiangsheng; Yu, Qiaoling; Li, Y.; Huang, Juanjuan; Li, J.; Ju, Yang; Li, H.; Zhang, G.; Ren, Wenzhi; Zhang, X.

doi:10.1111/pim.12024

Cited by 17 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In many studies regarding development of vaccines against T. gondii , encouraging outcomes were obtained when the antigens were delivered as DNA vaccines . In this research, DNA vaccination with TgMDH demonstrated significant results; however, comparisons between the immunological changes and protection induced by TgMDH as DNA vaccine and recombinant protein need to be further researched.…”

Section: Discussionmentioning

confidence: 82%

Immunological response and protection of mice immunized with plasmid encoding Toxoplasma gondii glycolytic enzyme malate dehydrogenase

Hassan

Wang

et al. 2014

Parasite Immunology

View full text Add to dashboard Cite

Toxoplasma gondii Malate dehydrogenase (TgMDH) plays an important role as part of the energy production cycle. In this investigation, immunological changes and protection efficiency of this protein delivered as a DNA vaccine have been evaluated. Mice were intramuscularly immunized with pTgMDH, followed by challenge with virulent T. gondii RH strain, 2 weeks after the booster immunization. Compared to the control groups, the results showed that pTgMDH has stimulated specific humoral response as demonstrated by significant high titers of total IgG and subclasses IgG1 and IgG2a , beside IgA and IgM, but not IgE. Analysis of cytokine profiles revealed significant increases of IFN-γ, IL-4 and IL-17, while no significant changes were detected in TGF-β1. In cell-mediated response, both T lymphocytes subpopulations CD4(+) and CD8(+) were positively recruited as significant percentages were recorded in response to immunization with TgMDH. Significant long survival rate, 17 days, has been observed in the TgMDH vaccinated group, in contrast with control groups which died within 8-9 days after challenge. These results demonstrated that TgMDH could induce significant immunological responses leading to a considerable level of protection against acute toxoplasmosis infection.

show abstract

Section: Discussionmentioning

confidence: 82%

Immunological response and protection of mice immunized with plasmid encoding Toxoplasma gondii glycolytic enzyme malate dehydrogenase

Hassan

Wang

et al. 2014

Parasite Immunology

View full text Add to dashboard Cite

show abstract

“…The in vitro transfection assay was performed as previously described [41]. Briefly, before transfection, 2 × 10 4 HEK293T cells were seeded in a 6-well plate.…”

Section: Methodsmentioning

confidence: 99%

DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB/c mice

et al. 2013

View full text Add to dashboard Cite

BackgroundToxoplasma gondii is a widespread intracellular parasite, which infects most vertebrate animal hosts and causes zoonotic infection in humans. Vaccine strategy remains a promising method for the prevention and control of toxoplasmosis. T. gondii GRA4 protein has been identified as a potential candidate for vaccine development. In our study, we evaluated the immune response induced by four different immunization vaccination strategies encoding TgGRA4.MethodsBALB/c mice were intramuscularly (i.m.) immunized four times according to specific immunization schedules. Generally, mice in experimental groups were immunized with polypeptide, pGRA4, peptide/DNA, or DNA/peptide, and mice in the control groups were injected with PBS or pEGFP. After immunization, the levels of IgG antibodies and cytokine productions were determined by enzyme-linked immunosorbent assays (ELISA). The survival time of mice was also evaluated after challenge infection with the highly virulent T. gondii RH strain.ResultsThe results showed that mice vaccinated with different immunization regimens (polypeptide, pGRA4, peptide/DNA, or DNA/peptide) elicited specific humoral and cellular responses, with high levels of total IgG, IgG2a isotype and gamma interferon (IFN-γ), which suggested a specific Th1 immunity was activated. After lethal challenge, an increased survival time was observed in immunized mice (11.8 ± 4.8 days) compared to the control groups injected with PBS or pEGFP (P < 0.05). Mice injected with PBS or pEGFP died within 8 days, and there was no significant difference in the protection level in two groups (P > 0.05).ConclusionsThese results demonstrated that this DNA prime and peptide boost immunization protocol encoding the TgGRA4 can elicit the highest level of humoral and cellular immune responses compared to other immunized groups, which is a promising approach to increase the efficacy of DNA immunization.

show abstract

“…Over the past 4 years, toxoplasmosis DNA vaccination studies expanded to the use of many new parasite antigens, several of which yielded promising protective outcomes ( Table 2 ). Among these latest developments, several single-antigen vaccines were successful in producing survivors from a lethal infection challenge, such as ROP8, TgCyP, and GRA6 with a range of survival rate between 37.5-50.0% [ 52 , 53 , 54 ]. Another subset of these DNA vaccine studies produced a significant increase in survival time (≥3 weeks) but no survivors following a lethal challenge, which was the ROP13, ROP16, ROP18, MIC13, and eIF4A [ 34 , 36 , 55 , 56 , 57 ].…”

Section: Dna Vaccinesmentioning

confidence: 99%

Recent Advances in Toxoplasma gondii Immunotherapeutics

Lim

Othman

2014

Korean J Parasitol

View full text Add to dashboard Cite

Toxoplasmosis is an opportunistic infection caused by the protozoan parasite Toxoplasma gondii. T. gondii is widespread globally and causes severe diseases in individuals with impaired immune defences as well as congenitally infected infants. The high prevalence rate in some parts of the world such as South America and Africa, coupled with the current drug treatments that trigger hypersensitivity reactions, makes the development of immunotherapeutics intervention a highly important research priority. Immunotherapeutics strategies could either be a vaccine which would confer a pre-emptive immunity to infection, or passive immunization in cases of disease recrudescence or recurrent clinical diseases. As the severity of clinical manifestations is often greater in developing nations, the development of well-tolerated and safe immunotherapeutics becomes not only a scientific pursuit, but a humanitarian enterprise. In the last few years, much progress has been made in vaccine research with new antigens, novel adjuvants, and innovative vaccine delivery such as nanoparticles and antigen encapsulations. A literature search over the past 5 years showed that most experimental studies were focused on DNA vaccination at 52%, followed by protein vaccination which formed 36% of the studies, live attenuated vaccinations at 9%, and heterologous vaccination at 3%; while there were few on passive immunization. Recent progress in studies on vaccination, passive immunization, as well as insights gained from these immunotherapeutics is highlighted in this review.

show abstract

The protective effect of aDNAvaccine encoding theToxoplasma gondiicyclophilin gene inBALB/cmice

Cited by 17 publications

References 36 publications

Immunological response and protection of mice immunized with plasmid encoding Toxoplasma gondii glycolytic enzyme malate dehydrogenase

Immunological response and protection of mice immunized with plasmid encoding Toxoplasma gondii glycolytic enzyme malate dehydrogenase

DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB/c mice

Recent Advances in Toxoplasma gondii Immunotherapeutics

Contact Info

Product

Resources

About